While IL-1 inhibition has demonstrated efficacy in conditions such as systemic juvenile idiopathic arthritis and autoinflammatory syndromes, its impact in RA has been less pronounced (Pardeo et al., 2021; Arnold et al., 2022). Here, IL1A is linked to systemic-onset juvenile idiopathic arthritis.